Please login to the form below

Not currently logged in
Email:
Password:

Cabometyx

This page shows the latest Cabometyx news and features for those working in and with pharma, biotech and healthcare.

European Commission approves Opdivo plus Cambometyx for advanced kidney cancer

European Commission approves Opdivo plus Cambometyx for advanced kidney cancer

Twice as many patients responded to Opdivo plus Cabometyx compared to Sutent – 55.7% and 27.1%, respectively. ... Opdivo/Cabometyx was also associated with a disease control rate of 88.2% versus 69.9% with Sutent.

Latest news

More from news
Approximately 9 fully matching, plus 10 partially matching documents found.

Latest Intelligence

  • Charting a course for expansion Charting a course for expansion

    The February deal, which gives Ipsen commercialisation and development rights outside the US, has seen Cabometyx take off rapidly. ... It showed that Cabometyx can decrease the rate of disease progression or death by 31% in advanced renal cell carcinoma

More from intelligence
Approximately 1 fully matching, plus 0 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Aurora Healthcare Communications

We're a leading healthcare strategic communications agency helping pharmaceutical companies adapt fast to improve the lives of patients and healthcare...

Latest intelligence

Ask the writers: Transitioning from academia to medical writing
Porterhouse Medical's talented writers talk about their transition from academia and give advice to those people considering a career in medical writing...
Strategic launch planning: familiar framework, new mindset
By James Aird...
Guide
How to embrace behavioural science principles in healthcare MR...